Navigating New Approaches for Glaucoma Management: The Role of Nitric Oxide (Archived CE Monograph)

This educational activity has expired. You will not be able to claim credit for this activity.

Activity Description and Purpose

To address the educational needs of optometrists, this case-based program will focus on elucidating the role of nitric oxide in glaucomatous eyes, including treatment strategies that use nitric oxide’s mechanism of action on the trabecular meshwork to increase aqueous humor outflow and to achieve target intraocular pressure levels via new therapeutic options. Case discussions will interpret clinically relevant data supporting the efficacy and safety of this nitric oxide–containing treatment option. The desired results of this activity are for optometrists to improve their management of patients with glaucoma early in the disease process when outflow treatments can be most effective in helping prevent glaucoma progression.

Target Audience

This educational activity is intended for optometrists.

Learning Objectives

Upon completion of this activity, participants will be better able to:

  • Describe the downstream signaling effects of nitric oxide in relation to glaucoma
  • Discuss the effects of nitric oxide on the trabecular meshwork
  • Apply data from clinical trials on nitric oxide–donating agent(s) for lowering intraocular pressure
Course summary
Course opens: 
11/01/2019
Course expires: 
10/31/2025

Disclosures

Michael Chaglasian, OD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerie Pharmaceuticals, Inc; Alcon; Bausch & Lomb Incorporated; Carl Zeiss Meditec, Inc; Glaukos Corporation; Novartis Pharmaceuticals Corporation; and Reichert, Inc; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Aerie Pharmaceuticals, Inc; Bausch & Lomb Incorporated; Carl Zeiss Meditec, Inc; Glaukos Corporation; Novartis Pharmaceuticals Corporation; and Reichert, Inc; Contracted Research: Heidelberg Engineering GmbH; and Topcon Medical Systems, Inc.

Richard J. Madonna, MA, OD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerie Pharmaceuticals, Inc; Allergan; Bausch & Lomb Incorporated; Carl Zeiss Meditec, Inc; Heidelberg Engineering GmbH; and Novartis Pharmaceuticals Corporation; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Aerie Pharmaceuticals, Inc; Allergan; Bausch & Lomb Incorporated; Carl Zeiss Meditec, Inc; Heidelberg Engineering GmbH; and Novartis Pharmaceuticals Corporation.

Danica Marrelli, OD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerie Pharmaceuticals, Inc; Allergan; Bausch & Lomb Incorporated; Carl Zeiss Meditec, Inc; and Novartis Pharmaceuticals Corporation; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Aerie Pharmaceuticals, Inc; Bausch & Lomb Incorporated; and Carl Zeiss Meditec, Inc.

Editorial Support Disclosures

The planners and staff of MedEdicus LLC have no relevant commercial relationships to disclose.

Disclosure Attestation

Each of the contributing physicians listed above have attested to the following:

  1. that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
  2. that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
  3. that all reasonable clinical alternatives will be discussed when making practice recommendations.

Accreditation Statement

COPE approved for 1.5 CE credits for optometrists.
COPE Course ID: 65097-GL
COPE Course Category: Glaucoma

Administrator:

Product Usage in Accordance With Labeling

Please refer to the official prescribing information for each drug and/or device discussed in this activity for approved indications, contraindications, and warnings.

Grantor Statement

This continuing education activity is supported through an unrestricted educational grant from Bausch & Lomb Incorporated

Sponsored by

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the State University of New York College of Optometry, MedEdicus LLC, Bausch & Lomb Incorporated, or Optometry Times.

This CE activity is copyrighted to MedEdicus LLC ©2019. All rights reserved. 186

Please login or register to take this course.

This educational activity has expired. You will not be able to claim credit for this activity.